medRxiv preprint doi: https://doi.org/10.1101/2023.12.02.23299314; this version posted December 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

1 Microsatellites reveal high polymorphism and high potential for use in

2 antimalarial efficacy studies in areas with different transmission

3 intensities in mainland Tanzania

4

Deus S. Ishengoma^{1, 2, 3*}, Celine I. Mandara¹, Rashid A. Madebe¹, Marian
Warsame⁴, Billy Ngasala^{5,6}, Abdunoor M. Kabanywanyi⁷, Muhidin K.
Mahende^{7,8}, Erasmus Kamugisha⁸, Reginald A. Kavishe⁹, Florida Muro⁹,
Renata Mandike¹⁰, Sigsbert Mkude¹⁰, Frank Chacky¹⁰, Ritha Njau¹¹, Troy
Martin¹², Ally Mohamed¹⁰, Jeffrey A. Bailey¹³, Abebe A. Fola¹³

10

¹*National Institute for Medical Research, Dar es Salaam, Tanzania*

- ¹² ²Faculty of Pharmaceutical Sciences, Monash University, Melbourne, Australia
- ¹³ ³Harvard T. H Chan School of Public Health, Harvard University, Boston, MA,
- 14 USA
- ⁴Gothenburg University, Gothenburg, Sweden.
- ¹⁶ ⁵Department of Parasitology, School of Public Health, Muhimbili University of
- 17 Health and Allied Sciences, Dar es Salaam, Tanzania
- ⁶Department of Women's and Children's Health, International Maternal and
- 19 Child Health (IMCH), Uppsala University, Uppsala, Sweden
- 20 ⁷Ifakara Health Institute, Dar es Salaam, Tanzania
- ⁸Catholic University of Health and Allied Sciences/Bugando Medical Centre,
 Mwanza, Tanzania
- ⁹¹Kilimanjaro Christian Medical University College/Kilimanjaro Christian
 Medical Centre, Moshi, Tanzania
- ¹⁰National Malaria Control Programme, Ministry of Health, Dodoma, Tanzania
- ¹¹Malariologist and Public Health Specialist, Dar es Salaam, Tanzania
- ¹²HIV Vaccine Trials Network, Fred Hutch Cancer Research Centre, Seattle,
 Washington, USA
- ¹³Department of Pathology and Laboratory Medicine, Warren Alpert Medical
- 30 School, Brown University, Providence, RI, USA.
- 31
- 32
- 33 *Corresponding author
- 34 Email: <u>deusishe@yahoo.com</u>
- 35
- 36
- 37

38 Abstract

39 Background

Tanzania is currently implementing therapeutic efficacy studies (TES) in areas 40 of varying malaria transmission intensities as per the World Health 41 42 Organization's (WHO) recommendations. In TES, distinguishing reinfection 43 from recrudescence is critical for the determination of antimalarial efficacy. 44 Recently, the WHO recommended genotyping polymorphic coding genes 45 (msp1, msp2, and glurp) and highly polymorphic neutral microsatellites in 46 *Plasmodium falciparum* to adjust the efficacy of antimalarials in TES. This study 47 assessed the polymorphisms of six neutral microsatellite markers and their 48 potential use in TES, which are routinely performed in Tanzania.

49 **Methods**

50 P. falciparum samples were obtained from four TES sentinel sites, Kibaha 51 (Pwani), Mkuzi (Tanga), Mlimba (Morogoro), and Ujiji (Kigoma), between April 52 and September 2016. Parasite genomic DNA was extracted from dried blood 53 spots on filter papers using commercial kits. Genotyping was performed using 54 six microsatellites (Poly-a, PfPK2, TA1, C3M69, C2M34 and 2490) by the 55 capillary method, and the data were analyzed to determine the extent of polymorphisms and genetic diversity at the four sites. 56

57 Results

Overall, 83 (88.3%) of the 94 samples were successfully genotyped (with 58 59 positive results for \geq 50.0% of the markers), and >50.0% (range = 47.6-59.1%) 60 were polyclonal, with the mean multiplicity of infection ranging from 1.68 to 1.88 61 among the four sites. There was high genetic diversity but limited variability among the four sites based on mean allelic richness ($R_s = 7.48$, range= 7.27-62 8.03, for an adjusted minimum sample size of 18 per site) and mean expected 63 heterozygosity ($H_e = 0.83$, range= 0.80-0.85). Cluster analysis of haplotypes 64 using STRUCTURE, principal component analysis, and pairwise genetic 65 differentiation (F_{ST}) did not detect any population structure, and isolates 66 clustered independently of geographic origin. Of the six markers, Poly-a was 67 the most polymorphic, followed by C2M34, TA1 and C3M69, while 2490 was 68 69 the least polymorphic.

70 Conclusion

- 71 Microsatellite genotyping revealed high polyclonality and genetic diversity but
- 72 without any significant population structure. Poly-α, C2M34 and TA1 were the
- 73 top polymorphic markers and could be adopted for use in TES in Tanzania.
- 74
- 75 Key words: Plasmodium falciparum, falciparum malaria, therapeutic efficacy
- 76 studies, microsatellites, Tanzania.
- 77

medRxiv preprint doi: https://doi.org/10.1101/2023.12.02.23299314; this version posted December 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

78 Background

79 Malaria case management is one of the main interventions for malaria control, and together with vector control tools have significantly contributed to the 80 reduction in morbidity and mortality that was reported between 2000 and 2015 81 82 [1]. However, this strategy has been compromised by antimalaria drug resistance which led to the withdrawal of chloroquine and SP and replacing 83 84 them with artemisinin combination therapy (ACT) [2]. In 2006, Tanzania introduced ACTs with artemether-lumefantrine (AL) for the treatment of 85 86 uncomplicated malaria, and the drug was officially rolled out in January 2007 [3]. AL, which is a fixed-dose combination of artemether and lumefantrine, has 87 88 been effectively used for the past 16 years for the treatment of malaria [4], and studies undertaken in Tanzania have shown that it has maintained high and 89 optimal efficacy and safety with high cure rates and minimal safety concerns 90 [5–9]. Previous reports showed that ART-R emerged in the Mekong Subregion 91 92 of Southeast Asia following deployment of ACTs and was associated with 93 delayed parasite clearance [10,11], extended survival of ring stage [12,13] and 94 mutations in the kelch13 (k-13) gene [14–16]. Until 2018, mutations associated 95 with artemisinin resistance had not been reported in Africa [4], and ACTs retained high cure rates for the treatment of uncomplicated falciparum malaria 96 97 [4]. However, recent studies confirmed artemisinin partial resistance in Rwanda with mutations at codon R561H (>5%) of the k-13 gene and day 3 positivity 98 99 rates (>10%), but AL still had sufficient cure rates (>90%) [17,18]. Similarly, 100 artemisinin partial resistance has been reported in Uganda with mutations in 101 the k-13 gene at codons A675V and C469Y [19], Tanzania with 561H mutations 102 (Ishengoma D. Unpublished data) and in Eritrea for mutations at codon R622I 103 [20]. For lumefantrine, studies conducted in Tanzania [9] and elsewhere have reported an increase in polymorphisms in the multidrug resistance 1 gene 104 (*mdr1*), which are associated with reduced susceptibility to lumefantrine [21]. 105 106 The impacts of the polymorphism in the *mdr1* gene on the performance of AL are not clearly known, and thus, sustained surveillance is needed to monitor 107 108 the performance of this important ACT and allow early detection of any 109 emergence of resistance before its efficacy is compromised.

110

111 In Tanzania, the National Malaria Control Programme (NMCP) and its partners have been collaboratively implementing therapeutic efficacy studies (TES) 112 since 1997 [22,23]. These TES are based on the WHO standard protocol 113 [24,25] and aim at monitoring the efficacy and safety of antimalarials used for 114 115 the treatment of uncomplicated malaria in children aged six months to 10 years. 116 For Tanzania, studies have focused on first-line antimalarial (artemether-117 lumefantrine – AL) and alternative artemisinin-based combination therapies (ACTs). The current alternative ACTs covered in TES include artesunate-118 119 amodiaquine (ASAQ), which is the first-line drug in Zanzibar [26], and dihydroartemisinin-piperaquine, which was included in the National Guidelines 120 121 for Diagnosis and Treatment of Malaria from 2014 [22,27]

122

According to the WHO protocol [24,28,29], TES has two components: field data 123 and sample collection and laboratory analyses. The laboratory analyses aim at 124 125 distinguishing recrudescent from new infections in patients with recurrent 126 infections and generating data of molecular markers in the genes associated 127 with resistance or reduced sensitivity/susceptibility of the parasites to the drugs. 128 To distinguish recrudescent from new infection, the old WHO protocol, which was developed in 2008, recommended genotyping of three polymorphic genes, 129 130 including merozoite surface protein 1 and 2 (msp1 and msp2) and glutamaterich protein (*glurp*) [29]. Recently, the WHO has recommended a new protocol 131 132 that recommends genotyping both msp1 and msp2 and one or two highly 133 polymorphic microsatellite markers [30]. Several microsatellite makers have 134 been utilized in studies of malaria parasites, but they differ in their level of polymorphisms and informativeness [13,31]. Of the different microsatellites, 135 WHO recommends using poly-A and any of the other two markers, TAE1 and 136 Pfk2. However, these markers have not been optimized in different countries to 137 determine if they are indeed sufficiently polymorphic and sensitive and can 138 139 reliably be used for genotyping within TES. This study was therefore undertaken to assess the polymorphisms of six microsatellite markers (Poly-A, 140 141 PfPK2, TA1, C3M69, C2M34 and 2490) for potential use in TES in Tanzania. 142 The findings provide important information on these markers and parasite populations in the country and will facilitate future genomic studies and their 143 144 application in TES and malaria surveillance as well.

145 **Materials and Methods**

Study sites 146

The samples used for this study were obtained from clinical malaria cases 147 sampled in a TES that was conducted during and after the long rainy season 148 149 between April and September 2016 [9]. It was undertaken in four geographically and epidemiologically distinct areas of Tanzania (Kibaha - Pwani, Mkuzi -150 151 Tanga, Mlimba – Morogoro and Ujiji - Kigoma), and these sites have been NMCP sentinel sites for monitoring of antimalarial efficacy since 1997 (Figure 152 153 1) [22,23]. The study sites were selected to represent distinct geographic areas 154 of Tanzania. In Kibaha district of the coastal region (Pwani), the study was conducted at Yombo Dispensary, which is located in an area that has 155 transitioned from high to low malaria transmission (with prevalence by mRDTs 156 in under-fives of <10% in 2017)[32-34]. In Tanga region, the study site was 157 Mkuzi health center, which is located in Muheza district. Areas around Mkuzi 158 159 have reported a progressive decline in malaria prevalence (in individuals aged < 20 years) from over 80% in the 1990s to <10% in 2017 [35,36]. The Ujiji health 160 161 center is located in Kigoma urban district of the Kigoma region. Parasite 162 prevalence among under-fives (by mRDTs) in Kigoma increased from 19.6% in 2007 to 38.1% in 2016, followed by a decline to 24.4% in 2017, but this was the 163 164 highest prevalence in the country [32–34]. The fourth site of Mlimba health center (parasite prevalence among under-fives in 2017 was <10%) is located in 165 166 Kilombero district of Morogoro region and has experienced a significant decline 167 in malaria burden in the last two decades [37]. Additional details of the study 168 sites were given elsewhere [9,38].

medRxiv preprint doi: https://doi.org/10.1101/2023.12.02.23299314; this version posted December 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



169

Figure 1. Map of Tanzania showing the four study sites of Kibaha, Mkuzi,
Mlimba, and Ujiji. (Parasite prevalence data were obtained from the School
Malaria Parasitological Survey of 2015[39].

173

174 Study design and target population

Samples used for this analysis were collected during a single-arm prospective *in vivo* TES that assessed the therapeutic efficacy and safety of artemetherlumefantrine (AL) for the treatment of uncomplicated falciparum malaria and markers of artemisinin and lumefantrine resistance [9]. The study recruited 344 out of the 963 febrile children aged 6 months to 10 years who were screened according to the WHO protocol [24,25].

181

182 Sample collection

Enrolled children were treated with AL and followed up for 28 days with clinical and parasitological assessments in the first three days post-treatment (day 1, 2 and 3) and once weekly from day 7 to 28 [9]. Thick and thin films were taken for the detection of malaria parasites during each visit. Dried blood spots (DBS) on filter papers were also collected at enrollment and from day 7 onward for molecular analyses of malaria parasites.

189 Sample processing and genotyping

Parasite genomic DNA was extracted from DBS using QIAamp DNA mini-kits 190 (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. 191 192 Analysis of six neutral microsatellite markers was undertaken at the Centers for 193 Disease Control and Prevention's (CDC) Malaria Laboratory in Atlanta, USA. A 194 total of 94 samples were collected on day zero among patients with recurrent 195 infections and a random selection of other samples from patients without 196 recurrent infections collected on day zero were selected for microsatellite 197 genotyping. These samples were analyzed to distinguish recrudescent from new infections as previously reported [9] and to determine genetic diversity in 198 199 the study populations. The microsatellite markers (TA1 on chromosome 6, Poly 200 $-\alpha$ on chromosome 4, PfPK2 on chromosome 12, 2490 on chromosome 10, 201 C2M34-313 on chromosome 2 and C2M69-383 on chromosome 3) were genotyped by nested PCR for all except C2M34-313 and C2M69-383 (which 202 203 were analyzed with a single step PCR). Fragment size was measured by 204 capillary electrophoresis on ABI 3033 (Applied Biosystems) and scored using 205 GeneMapper® Software Version 4.0 (Applied Biosystems) [40,41].

206

207 **Ethical considerations**

208 Ethical clearance was obtained from the medical research coordinating 209 committee (MRCC) of the National Institute for Medical Research (NIMR), while 210 permission to conduct the study at the health facilities was sought in writing 211 from the relevant regional and district medical authorities. Ethical clearance 212 from the CDC was not needed because the assessments performed at the CDC 213 Malaria Laboratory, using samples without linked identifiers (deidentified 214 samples), were determined by the CDC Center of Global Health's Human Research Protection Coordinator to not constitute an engagement in human 215 subjects' research. Informed consent (oral and written) was obtained from 216 217 parents or guardians before patients were screened to assess their eligibility for possible inclusion in the study. 218

- 219
- 220
- 221
- 222

223 Data analysis

224 Population genetic analysis

GeneScan chromatograms were analyzed using GeneMapper® Software 225 226 Version 4.0 (Applied Biosystems) with an internal size standard of 350 Rox. 227 The stutter window was set to 2.5 for 2 bp repeats, 3.5 for 3 bp repeats and 4.5 228 for 4 bp repeats. The stutter ratio was set to 0.4 for the four markers, and for 229 the remaining two markers (C2M34 and C3M69), a relatively higher stutter ratio 230 (0.6) was set, as they showed greater stuttering during manual inspection of 231 chromatograms. A cut-off of 1,000 relative fluorescence units (RFUs) was used 232 to distinguish true peaks from background signals. All dominant peaks (i.e., 233 those peaks within the size range with the highest RFUs) and any additional 234 alleles with a minimum 30% height of the dominant allele were scored. All 235 chromatograms were inspected manually to confirm call quality. Then, samples with low RFUs were re-analysed with a minimum fluorescence of 200 RFU. 236 237 Microsatellite haplotypes comprising more than 3 (50%) successfully typed 238 markers were selected for further analysis.

239

240 For downstream population genetics analysis, multilocus microsatellite allele data were converted into different formats using CONVERT software version 241 242 1.3.1. The number of genetically distinct parasite clones (multiplicity of infection, 243 MOI) was calculated considering the maximum number of alleles detected at 244 any of the six microsatellite loci. The number of clones for each population was 245 determined by summing the total number of clones per isolate. The mean MOI 246 for each population was calculated by dividing the total number of clones 247 detected by the number of samples. Genetic diversity was measured by 248 calculating allelic richness (R_s) and expected heterozygosity (H_e) using FSTAT software version 2.9.3.2 [42]. As a measure of inbreeding within populations 249 (non-random association of alleles), the standardized index of association (I_A^S) 250 251 was used to measure multilocus linkage disequilibrium (LD) in each parasite 252 population using LIAN version 3.6, applying a Monte Carlo test with 100,000 re-253 sampling steps [43].

254

255 STRUCTURE version 2.3.4 [44] was used to determine the number of 256 population clusters (K) and whether haplotypes clustered according to their

257 geographic origin. The analysis was run 20 times for K = 1 to 20, for 100,000 Monte Carlo Markov Chain (MCMC) iterations after a burn-in period of 100,000, 258 259 and using the admixture model. To obtain the optimal K value, the method of Evanno et al [44]was used to calculate ΔK from the log probability of the data 260 261 (LnP[D]) using STRUCTURE HARVESTER [45]. The STRUCTURE bar plots 262 (ancestry coefficients) were visualized using Cluster Markov Packager Across 263 K (CLUMPAK) [46]. Genetic differentiation between populations was measured by calculating the F_{ST} statistic according to Nei [47]. Estimation of average 264 265 heterozygosity and genetic distance from a small number of individuals was performed using the pairwise.neifst function available in the hierfstat R 266 267 package[48]. The Mantel test was performed to measure the associations between genetic distance and geographical distance between catchments 268 using the Mantel function in the R adegenet package [49]. To assess haplotype 269 270 relatedness, the genetic distance metric (1-pairwise allele sharing $(P_{\rm S})$) was 271 calculated and used to generate phylogenetic trees using the bionj Ape R 272 package [50].

273

274 Results

275 From a total of 94 *P. falciparum* samples, 83 were successfully genotyped, and 276 all gave positive results for 3 (50%) or more microsatellite markers (Table 1). 277 Only single infections or dominant haplotypes constructed from multiple 278 infection data were included in downstream population genetic analyses. The 279 number of clones per sample ranged from 1 to 4, and a total of 38 (45.8%) 280 samples had single infections, followed by samples carrying two distinct 281 parasite clones (n= 31, 37, 3%), three (n= 12, 14,45%), and only two samples 282 carried four distinct clones. Overall, at least 38% of the samples in each 283 population contained more than one parasite clone (polyclonal), and there was limited variability in the mean MOI among populations (average MOI ranged 284 285 from 1.68 to 1.88) (Table 1).

286

287

288

- 290 Table 1. Population genetic metrics of four Tanzanian P. falciparum
- 291 populations

Population	Prevalence (%)†	N	n	h	<i>R₅</i> ±SD	<i>H_e</i> ±SD	<i>I</i> A ^S	MOI	Polyclonality (%) #
Kibaha	13.8	25	21	19	8.03 <u>+</u> 2.8	0.85 <u>+</u> 0.12	0.1569**	1.76	47.6
Ujiji- Kigoma	35.6	23	22	22	7.48 <u>+</u> 2.1	0.84 <u>+</u> 0.10	0.1736**	1.88	59.09
Mkuzi- Muheza	22.6	25	22	22	7.79 <u>+</u> 2.4	0.82 <u>+</u> 0.14	0.1095**	1.68	54.5
Mlimba- Kilombero	30.2	21	18	18	7.56 <u>+</u> 2.3	0.80 <u>+</u> 0.20	0.0903*	1.72	55.5

292 *N*=total number of samples; n=number of samples successfully genotyped; h= 293 number of unique haplotypes; $R_s = Allelic$ richness, H_{e} = expected 294 heterozygosity, I_A^S =standard index of association as a measure of multilocus linkage disequilibrium (LD), MOI= multiplicity of infection (mean number of 295 clones per infection); Polyclonality= proportion of samples containing more than 296 one parasite clone +Prevalence of malaria in the study districts in the 2015 297 school malaria parasitological survey [10] *=p-value<0.01, **=p-value<0.001; 298 *#Polyclonality (%) refers to the proportion of infections with >1 clones.* 299

300

No significant difference in mean multiplicity of infection among 301 302 populations

In malaria endemic countries such as Tanzania, individuals often carry more 303 than one parasite clone that is genetically different, referred to as multiplicity of 304 305 infections (MOI), also known as complexity of infection (COI). MOI occurs either 306 due to repeated bites of infective mosquitoes or multiple clones in a single 307 mosquito inoculum [51] and decreases with declining transmission. Here, we 308 found a mean MOI of 1.73 across populations (range = 1-4 parasite clones per 309 sample), and there was no statistically significant difference among the four 310 populations (Kruskal–Wallis test) (Figure 2).



- 312 313
- 314

315 Figure 2. Multiplicity of infection in four Tanzanian P. falciparum 316 populations.

317 Box and whisker plots were generated from the number of clones determined 318 for each microsatellite marker per population using R software. Dots indicate a 319 haplotype, boxes indicate the interguartile range, the line indicates the median 320 and the whiskers show the 95% confidence intervals. The numbers above the box plot indicate pairwise comparative p values between populations showing 321 a lack of significant difference in MOI among the four sites. 322

323 324

The association between polyclonality (proportion of multiple infections) and 325 parasite prevalence was assessed, and a positive correlation between 326 327 polyclonality and malaria prevalence was observed (based on 2015 school survey data) per population (R = 0.97, *p*-value = 0.035, Spearman Rank 328 329 Correlation) (Figure 3). Polyclonality was lower in Kibaha and Muheza, which 330 had a lower prevalence compared to Ujiji, with higher polyclonality and a higher 331 prevalence of malaria.



332 333 Figure 3. Association between the parasite prevalence (by mRDT) and 334 proportion of multiple infections (polyclonality) in four Tanzanian P. falciparum populations. The graph indicates a significant positive association 335 between polyclonal infections and parasite prevalence across different 336 geographic areas. Dots indicate population-level prevalence and proportion of 337 polyclonal infections; the blue line indicates the Spearman Rank Correlation 338 339 line, and the gray shaded region represents the 95% confidence interval.

340

341 High genetic diversity but significant multilocus linkage disequilibrium 342 (LD)

343 Of the 83 multilocus haplotypes from successfully genotyped P. falciparum isolates, 53 (63.8%) were complete genotypes, of which 51 (96.2%) were 344 345 unique and only two haplotypes were identical to each other within Kibaha population. Regardless of transmission intensity, there was high genetic 346 347 diversity of *P. falciparum*, with limited variability among the four parasite populations based on allelic richness (mean $R_{\rm S}$ = 7.27, range = 7.48-8.03, for 348 349 an adjusted minimum sample size of 18 per site) and expected heterozygosity 350 (mean $H_e = 0.83$, range = 0.80-0.85) (Table 1, Figure 4). However, according 351 to the Index of Association (I_A ^S) analysis, which is a measure of multilocus 352 linkage disequilibrium (which emerges when genotypes are related), all 353 parasite populations from the four sites showed significant multilocus LD (Table 354 1). This could be explained by the presence of some degree of inbreeding 355 despite high transmission in some areas-



360 361

Figure 4. Genetic diversity (Expected Heterozygosity (A), Allelic Richness 362 363 (B)) of *P. falciparum* in four geographic sites in Tanzania.

Box and Whisker plots were generated from the diversity metrics for each 364 microsatellite marker per population using R software. Boxes indicate the 365 366 interquartile range, the line indicates the median, and the whiskers show the 95% confidence intervals. 367

368 Furthermore, the diversity of microsatellite markers was assessed, and there was high variability in the alleles present per marker (A = 3 - 13) (Figure 5), with 369 variable frequency for the four different sites. The marker M2490 was the least 370 371 diverse microsatellite, with only a 3.5 mean number of distinct alleles detected 372 across the four populations, while PolyA was the most diverse microsatellite marker (A = 13, H_e =0.91), followed by C2M34 (A =11, H_e =0.89). These two 373 374 highly polymorphic markers (polyA and C2M34) and, if needed, together with 375 C3M69 and TA1 can be used for the detection of parasite clones in Tanzania. 376



377 378

Figure 5. Diversity of P. falciparum microsatellite markers among 379 parasites from the four sites in Tanzania. 380

Box and Whisker plots were generated from unique allele counts for each 381 382 microsatellite marker using R software. Boxes indicate the interguartile range, 383 the line indicates the median, and the whiskers show the 95% confidence intervals. 384

385 Lack of population structure and genetic differentiation

386 To investigate the presence of parasite population structure among the four 387 Tanzanian sites, cluster analysis of the haplotypes was conducted using 388 STRUCTURE version 2.3.4. No evidence of any population structure from K =389 2 - 4 was detected, and the ancestry of genotypes was equally split between 390 the genetic populations, showing no evidence of any population structure.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.02.23299314; this version posted December 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .





394 Structure bar plots representing individual ancestry coefficients are shown for 395 K=2, 3 and 4, and each vertical bar represents an individual genotype and the 396 membership coefficient (Q) within each of the genetic populations, as defined 397 by the different colours.

398

391

Further cluster analysis of haplotypes using principal component analysis
(PCA, with princomp function in R package) also did not detect any signature
of population structure and found no clustering of isolates by geographic origin
(Figure 7).



403

404 Figure 7. *Plasmodium falciparum* haplotype clustering.

A) Principal component analysis (PCA) of P. falciparum haplotypes. Dots
indicate individual microsatellite haplotypes, and colours indicate the four
sample collection sites. B) Percentage of variance explained by each principal
component (PC).

409 Gene flow and population connectivity

410 To assess gene flow and population connectivity, pairwise genetic differentiation based on Jost's D metric [52] and FST according to Nei [47] were 411 calculated among the four parasite populations using the pairwise.neifst 412 413 function available in the hierfstat R package. Very low levels of genetic 414 differentiation were observed between populations, confirming that P. 415 falciparum populations from these sites are highly panmictic (Table 2). We also 416 conducted the Mantel test to assess the correlation between pairwise genetic 417 distance and pairwise geographic distance in km as an indication of gene flow and parasite connectivity. The differentiation of parasite populations was not 418 419 statistically associated with geographical distance between populations and 420 therefore did not fit the Isolation-by-Distance model (Mantel statistic r = 0.072, p-value = 0.59). 421

422

Table 2. Pairwise genetic differentiation among parasite populations in 423 424 Tanzania

	Kibaha	Ujiji-Kigoma	Mkuzi-Muheza	Mlimba
Kibaha		0.01	0.009	0.038
Ujiji-Kigoma	0.37		0.005	0.001
Mkuzi-Muheza	0.22	0.14		0.003
Mlimba	0.34	0.37	0.24	

Top right = pairwise FST, Left bottom = pairwise Jost's D

425

426 Haplotype relatedness

427 To assess relatedness in *P. falciparum*, pairwise comparisons among all 428 isolates were conducted using the dist.gene command in the R Ape package. 429 The results showed that the majority of isolates had only one identical allele 430 among all six markers on average, and only a few isolates shared more than 431 50% of the alleles (three or more alleles). Phylogenetic analysis using 432 neighbour joining trees also confirmed a lack of population structure and 433 geographic clustering of genotypes. However, there were more haplotypes 434 clustering together within populations than between populations (Figure 8).



435

Figure 8 Relatedness of *P. falciparum* haplotypes in Tanzania. 436

Neighbour-Joining tree showing low levels of similarity of the multilocus P. 437 falciparum haplotypes between most isolates with similar haplotypes within 438 populations. Tips of the NJ tree are colour coded according to the four 439 440 geographic sites, and black diamonds indicate bootstrap values >50.

441

442 Discussion

443 This study included samples from four geographically distinct parasite populations (located 296 to 1211 km apart) from areas with different 444 445 transmission intensities to assess polymorphisms of six neutral microsatellite markers (Poly-a, PfPK2, TA1, C3M69, C2M34 and 2490) for potential use in 446 447 Tanzania. It also aimed at capturing the spatial genetic diversity and population structure of Tanzanian *P. falciparum*. The findings showed that four markers 448 449 (Poly- α , C2M34, C3M69 and TA1) had high diversity and could be adopted as validated markers for use in TES in Tanzania. As recently recommended by the 450 WHO [53] and a previous study that showed that a combination of four 451 microsatellite markers with sufficient diversity are needed in TES [54,55], these 452 microsatellite markers can be included in the revised workflow for TES in 453 454 Tanzania. The new panel should replace the old system based on genotyping 455 of *msp1*, *msp2* and *glurp* for distinguishing recrudescent from new infections in 456 ongoing TES in Tanzania. However, the areas around TES sites have

457 increasingly reported a decline in malaria transmission in the past two decades, 458 which suggests that continuous assessment of these and possibly other 459 microsatellite markers will be critical. This will ensure that high-resolution 460 markers are used and that the efficacy of antimalarials is not underestimated 461 due to the limited discrimination power of the markers. Additional methods such 462 as targeted amplicon sequencing can also be explored based on the capacity 463 of the laboratory, as recently recommended [56].

464

465 This study also showed high diversity and a lack of population structure and a high level of polyclonality despite varying malaria prevalence among the study 466 sites. The results suggest that these areas still have high malaria transmission 467 with little evidence of a control impact on transmission dynamics. However, a 468 significant correlation between parasite prevalence and polyclonality (as a 469 proxy of malaria measure of transmission intensity) was detected as expected, 470 471 given that in areas with higher malaria prevalence, humans are exposed to 472 multiple mosquito bites (superinfection) or infections with multiple clones (co-473 transmission) [57,58]. A strong correlation between parasite prevalence and 474 polyclonality has been reported in other studies [59-61] and needs to be monitored as a surrogate measure of potential changes in malaria transmission 475 476 due to the impacts of interventions. In Papua New Guinea, P. falciparum MOI was associated with parasite prevalence, but the diversity of the size 477 478 polymorphic markers remained high despite wide variation in prevalence at 479 different sites [59–61]. In contrast to these findings, a study in Indonesia [62] 480 reported lower genetic diversity, which was consistent with the low level of 481 malaria transmission at the study sites and could be a result of longer-term 482 sustained low transmission in this area compared to PNG and Tanzania.

483

Microsatellites are highly polymorphic, rapidly evolving and therefore may need long-term sustained low transmission to detect a signal of low diversity [31]. In PNG, studies have followed *P. falciparum* populations in declining transmission for over nine years and reported very minor changes in microsatellite diversity [63]. Moreover, high transmission intensity, high polyclonality and therefore high rates of recombination between distinct clones (outcrossing) might obscure the expected association between the MOI and transmission intensity

491 (prevalence) in different transmission zones. However, in low transmission areas such as South America, studies conducted in Ecuador and Peru reported 492 infections containing clonal parasites with clear population structure [64,65]. 493

494

495 In addition to the MOI as a proxy for transmission intensity, estimating the 496 extent of parasite genetic diversity and population structure is essential for a 497 deeper understanding of malaria epidemiology and transmission dynamics as 498 well as evaluating the impact of malaria control interventions [66]. Polymorphic 499 markers can also be used for the detection of different parasite clones in 500 different studies, including TES. In this study, it was shown that parasite genetic 501 diversity was high in the four Tanzanian sites regardless of the prevalence of 502 infection and that the respective parasite populations appeared to be highly 503 mixed with no clear genetic structure according to geographic origin. Thus, high 504 polymorphism at all sites and with all markers suggest that these markers 505 (especially the three topmost) can sufficiently be used in TES to distinguish 506 recurdescent from new infections, as recommended by the WHO [67].

507

508 Unlike the expectation that geographical isolation causes limited migration among subpopulations and geographical population structure, there was no 509 510 significant genetic differentiation (measured by F_{ST}) between distant and 511 nearby parasite populations. These results suggest high malaria transmission 512 intensity and/or extensive parasite migration throughout the country despite 513 significant improvement in malaria control strategies and drastic declines in 514 malaria transmission and disease burden in recent years. These findings 515 support previous observations where genetic diversity, geographic clustering 516 and inbreeding with strong LD as population genetic signals are expected in 517 low transmission areas, whereas high proportions of polyclonal infections, high 518 diversity and panmictic parasite populations were expected in areas with high 519 levels of transmission [31]. Generally, the levels of allelic diversity, parasite 520 outcrossing, and gene flow are high in African populations, low in South 521 American populations, and intermediate in Southeast Asian populations [31]. 522 The results of this study support a situation of continuing highly endemic 523 transmission dynamics in the country despite the expected substantial impact 524 of recent interventions on parasite prevalence in Tanzania.

525 The observed differences between this and recent studies, which were conducted in Tanzania and showed population structure among parasites from 526 different parts of the country[68,69], could be due to the markers used, SNPs 527 and WGS data compared to microsatellites used in the current study. Validation 528 529 of microsatellite markers for surveillance is important because they have been 530 the gold standard tool for malaria parasite population genetics for many years. 531 Furthermore, they are cheaper and easier to access for resource-limited laboratories. Ongoing and future studies will test different markers to increase 532 533 the resolution and robustness of capturing different population genetics metrics 534 that will be useful in assessing the impact of interventions and progress toward malaria elimination in Tanzania. Additionally, optimization of markers for 535 molecular genotyping of samples collected in TES needs to be pursued as 536 recently recommended [56]. 537

538

539 In contrast to the above findings, there was significant multilocus linkage 540 disequilibrium (LD) within populations, suggesting some level of inbreeding of 541 related parasites and repeated haplotypes, suggesting the occurrence of some 542 clonal transmission (monoclonal infections transmitted by the mosquito vector 543 in which parasite sexual recombination occurred between genetically identical 544 clones, albeit within the limitations of the markers used). An additional explanation for this finding could be the presence of subpopulations within 545 546 populations (Wahlund effect) [70], as the samples for this study were obtained 547 from clinical sites where patients usually come from different geographic areas 548 to seek medical care. Other studies in different malaria endemic countries found 549 similar results, significant LD despite high genetic diversity and a high 550 proportion of polyclonal infection in *P. falciparum* [71,72] and *P. vivax* [73,74]. 551 Detection of significant LD has important implications that could facilitate inbreeding and dispersal of multilocus drug resistance haplotypes or other 552 553 virulent strains. As transmission decreases in Tanzania due to intensive control 554 activities, as shown elsewhere [63], the presence of LD combined with a lack 555 of geographic population structure is highly likely to facilitate such events and 556 could be a future challenge in achieving malaria elimination.

There was high diversity in each of the microsatellite markers, indicating that 557 few highly polymorphic markers (C2M34 and PolyA) can be used to track the 558

559 MOI of *P. falciparum* in Tanzania. However, the genotyped markers may have limited the resolution of the population structure. The microsatellite panel used 560 had few markers (only six, with less than one per chromosome), many were 561 highly polymorphic (many alleles) and they are prone to technical artefacts [75]. 562 563 In addition, the sample size per population was relatively limited, with 564 approximately 20 samples successfully genotyped per site. Therefore, some 565 subtle differences between populations may not be detected. For example, in Kibaha, the same haplotype was found in two samples, while in all other 566 567 populations, all haplotypes were unique. If more samples had been genotyped, additional repeated haplotypes may be found, and diversity measures altered 568 569 somewhat. Further analysis of large numbers of samples (n>50) from additional 570 sites (again with varying transmission intensity) and utilizing larger numbers of highly polymorphic microsatellite markers [31,76,77] and/or comparing them 571 with SNP barcodes [78], amplicons [79-82] and WGS [83] will be needed in an 572 573 effort to optimize these markers. This should also be part of the ongoing 574 initiatives to establish a molecular surveillance platform to support policy and 575 decision-making by the Tanzanian NMCP in their strategy to eliminate malaria 576 by 2030. Nevertheless, the data generated provide findings of useful markers 577 for TES and parasite populations in Tanzania, showing that there are potentially 578 large, diverse and highly intermixing parasites despite strong reductions in 579 infection prevalence and disease burden. The findings also provide useful 580 baseline information for future monitoring of parasite populations in response 581 to ongoing malaria interventions.

582 Conclusion

583 Microsatellite genotyping revealed high polyclonality and genetic diversity but 584 without any significant population structure. Poly- α , C2M34, C3M69 and TA1 were the top polymorphic markers and could be adopted for use in TES in 585 586 Tanzania. Failure to reveal any significant population structure among parasite 587 populations could be due to high transmission or inherent limitations of small 588 numbers of microsatellite markers and sample size. More studies covering sites 589 with varying transmission intensity, more samples and using other genotyping 590 markers will be needed for establishing an effective molecular surveillance 591 system to support implementation of TES and area-specific interventions in 592 Tanzania and monitoring the impacts of the interventions.

593 Abbreviations

594	ACT	Artemisinin-based combination therapy
595	AL	Artemether-lumefantrine
596	CDC	Centers for Disease Control and Prevention
597	DBS	Dried Blood Spot
598	DNA	Deoxyribonucleic acid
599	MRCC	Medical Research Coordinating Committee
600	PARMA	US PMI-supported Antimalarial Resistance Monitoring in Africa
601		Network
602	PMI	US President's Malaria Initiative
603	NIMR	National Institute for Medical Research
604	NMCP	National Malaria Control Programme
605	PCR	Polymerase Chain Reaction
606	SNP	Single nucleotide polymorphism
607	TES	Therapeutic efficacy study
608	USA	United States of America
609	WHO	World Health Organization

610

Declarations 611

612 Ethical approval and consent to participate

This study was approved by the MRCC of NIMR, and permission to conduct the 613 614 study at the four sites was obtained from the district and regional medical authorities of the respective districts. Parents/guardians of all study participants 615 signed an informed consent before enrollment and provided permission to use 616 the samples for studying diversity among malaria parasites. 617

618 Availability of data

The microsatellite data set used for this study is available and has been submitted with this paper as supplemental table 1. Additional prevalence data can be obtained from the NMCP upon making an official request.

622

623 Competing interests

- The authors declare that they have no competing interests.
- 625

626 Funding

This study was funded by USAID under the US President's Malaria Initiative 627 (PMI) through MalariaCare (PATH). Laboratory analysis at CDC was supported 628 629 by USAID/PMI through PARMA. The training fellowship to DSI in Australia was 630 facilitated by BIO Ventures for Global Health (BVGH) through the WIPO Re:Search Fellowship Program with financial support from the Australian 631 632 Government through Funds-in-Trust to the World Intellectual Property Organization (WIPO). DSI was also partly supported by the DELTAS Africa 633 634 Initiative [grant 107740/Z/15/Z]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for 635 636 Accelerating Excellence in Science in Africa (AESA) and supported by the New 637 Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant 107740/Z/15/Z] 638 639 and the UK government. The views expressed in this publication are those of 640 the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome 641 Trust or the UK government.

642

643 Authors' contributions

DSI and RAM conceived of the idea and performed genotyping of the samples 644 at CDC. DSI, AF and AB performed the analysis of data, interpretation of results 645 646 and wrote the manuscript, with additional support from CIM, MW, BN, AMK, MKM, EK, RAK, FM, RM, SM, RN, AM and JB, who also designed the main 647 study and took part in field data collection. DSI and CIM supervised data 648 649 collection and overall implementation of the field work. TM provided technical and logistic support and was involved in project management at PATH. All the 650 651 authors have read and approved the final version of the manuscript.

652

653 Disclaimer

654 Ritha Njau and Marian Warsame are retired staff of the World Health 655 Organization. They alone are responsible for the views expressed in this publication, which do not necessarily represent the decisions, policy or views 656 of the World Health Organization. Furthermore, the findings and conclusions in 657 this paper are those of the authors and do not necessarily represent the official 658 position of the US Centers for Disease Control and Prevention. 659

660

Acknowledgments 661

662 The authors wish to thank parents/guardians of children for taking part in the study. They are grateful to the health facilities' staff, stakeholders, TES partners 663 and local health authorities for their support. Molecular analysis was undertaken 664 665 at the CDC with the support of the US President's Malaria Initiative-supported Antimalarial Resistance Monitoring in Africa (PARMA) Network. Technical and 666 logistic support was provided by the CDC, USAID/PARMA team (Drs. 667

668 Udhayakumar Venkatachalam, Eric Halsey, Meera Venkatesan, Naomi Lucchi, 669 Eldin Talundzic and Lynn Paxton), PMI - Tanzania (Chonge Kitojo, Gorge Greer and Erik Reaves) and NIMR staff are highly appreciated. Test drugs and filter 670 671 papers were provided by the WHO through its Global Malaria Programme. Thanks to PATH teams (Seattle, WA and Washington DC, USA) for financial 672 673 and logistics support. This study was sponsored by NIMR as the host institution 674 of TES coordination on behalf of the TES Taskforce. Special appreciation to Catherine Bakaria and Salehe Mandai for helping to finetune the final version of 675 676 the manuscript. Permission to publish this paper will be sought and granted by 677 the Director General of NIMR. 678

- 679 **Consent for publication**
- 680 Not applicable.

681 References

1. World Health Organization. World malaria report 2022 [Internet]. World 682 683 Health Organization: 2022. Available from: https://play.google.com/store/books/details?id=ST-hEAAAQBAJ 684

2. World Health Organization. Guidelines for the Treatment of Malaria [Internet]. 685 686 World Health Organization: 2006. Available from: https://play.google.com/store/books/details?id=Am83eI7_poUC 687

3. National guidelines for malaria diagnosis and treatment, 2006 [Internet]. [Dar 688 es Salaam]: National Malaria Control Programme; 2006. Available from: 689 690 http://www.loc.gov/catdir/toc/fy0805/2006316093.html

691 4. World Health Organization. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010-2019) [Internet]. World Health 692 Available 693 Organization: 2020. from: 694 https://play.google.com/store/books/details?id=oMFgEAAAQBAJ

5. Shayo A, Mandara CI, Shahada F, Buza J, Lemnge MM, Ishengoma DS. 695 Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of 696 697 uncomplicated falciparum malaria in North-Eastern Tanzania. Malar J 698 [Internet]. 2014;13:376. Available from: http://dx.doi.org/10.1186/1475-2875-699 13-376

700 6. Shayo A, Buza J, Ishengoma DS. Monitoring of efficacy and safety of 701 artemisinin-based anti-malarials for treatment of uncomplicated malaria; a 702 review of evidence of implementation of anti-malarial therapeutic efficacy trials 703 Tanzania. Malar J [Internet]. 2015;14:135. Available from: in 704 http://dx.doi.org/10.1186/s12936-015-0649-8

705 7. Mandara CI, Kavishe RA, Gesase S, Mghamba J, Ngadaya E, Mmbuji P, et 706 al. High efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine 707 for the treatment of uncomplicated falciparum malaria in Muheza and Kigoma 708 Districts, Tanzania. Malar J [Internet]. 2018;17:261. Available from: 709 http://dx.doi.org/10.1186/s12936-018-2409-z

710 8. Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, 711 Kamugisha E, et al. Efficacy and safety of artemisinin-based combination 712 therapy, and molecular markers for artemisinin and piperaguine resistance in 713 Mainland Tanzania. Malar J [Internet]. 2018;17:369. Available from: 714 http://dx.doi.org/10.1186/s12936-018-2524-x

9. Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, 715 et al. Efficacy and safety of artemether-lumefantrine for the treatment of 716 717 uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms 718 after a decade of using artemisinin-based combination therapy in mainland 719 Tanzania. Malar J [Internet]. 2019;18:88. Available from: http://dx.doi.org/10.1186/s12936-019-2730-1 720

721 10. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin 722 resistance in Plasmodium falciparum malaria. N Engl J Med [Internet].

723 2009;361:455–67. Available from: http://dx.doi.org/10.1056/NEJMoa0808859

724 11. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. 725 Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 726 [Internet]. 2008;359:2619-20. Available from: 727 http://dx.doi.org/10.1056/NEJMc0805011

12. Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, 728 729 et al. Drug resistance, K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science [Internet]. 2015;347:428-31. 730 Available from: http://dx.doi.org/10.1126/science.1260867 731

732 13. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel 733 phenotypic assays for the detection of artemisinin-resistant Plasmodium 734 falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. 735 Lancet Infect Dis [Internet]. 2013;13:1043-9. Available from: 736 http://dx.doi.org/10.1016/S1473-3099(13)70252-4

14. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et 737 738 al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. 739 Nature [Internet]. 2014;505:50-5. Available from: 740 http://dx.doi.org/10.1038/nature12876

741 15. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et 742 al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater 743 Mekong subregion: a molecular epidemiology observational study. Lancet 744 Infect Dis [Internet]. 2017;17:491-7. Available from: 745 http://dx.doi.org/10.1016/S1473-3099(17)30048-8

16. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread 746 747 of artemisinin-resistant Plasmodium falciparum in Mvanmar: a cross-sectional 748 survey of the K13 molecular marker. Lancet Infect Dis [Internet]. 2015;15:415-749 21. Available from: http://dx.doi.org/10.1016/S1473-3099(15)70032-0

750 17. Uwimana A, Legrand E, Stokes BH, Ndikumana J-LM, Warsame M, 751 Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-752 resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. 753 Nat Med [Internet]. 2020;26:1602-8. Available from: 754 http://dx.doi.org/10.1038/s41591-020-1005-2

755 18. Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, 756 et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, 757 758 therapeutic efficacy study. Lancet Infect Dis [Internet]. 2021;21:1120-8. 759 Available from: http://dx.doi.org/10.1016/S1473-3099(21)00142-0

19. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, 760 et al. Evidence of Artemisinin-Resistant Malaria in Africa. N Engl J Med 761 762 [Internet]. 2021;385:1163-71. Available from: 763 http://dx.doi.org/10.1056/NEJMoa2101746

20. Mihreteab S, Platon L, Berhane A, Stokes BH, Warsame M, Campagne P, 764

765 et al. Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria 766 in Eritrea. N Engl J Med [Internet]. 2023;389:1191-202. Available from: 767 http://dx.doi.org/10.1056/NEJMoa2210956

768 21. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, 769 Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine 770 resistance transporter and multidrug resistance 1 genes: parasite risk factors 771 that affect treatment outcomes for P. falciparum malaria after artemether-772 lumefantrine and artesunate-amodiaguine. Am J Trop Med Hyg [Internet]. 773 2014;91:833-43. Available from: http://dx.doi.org/10.4269/ajtmh.14-0031

774 22. EANMAT. Monitoring antimalarial drug resistance within National Malaria 775 Control Programmes: the EANMAT experience. Trop Med Int Health [Internet]. 776 2001:6:891-8. Available from: http://dx.doi.org/10.1046/j.1365-3156.2001.00799.x 777

778 23. East African Network for Monitoring Antimalarial Treatment (EANMAT). The 779 efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and 780 amodiaguine in East Africa: implications for sub-regional policy. Trop Med Int 781 Health [Internet]. 2003;8:860-7. Available from: 782 https://onlinelibrary.wiley.com/doi/10.1046/j.1360-2276.2003.01114.x

- 783 24. WHO. Malaria surveillance, monitoring and evaluation: a reference manual. 2018; 784
- 785 25. WHO. Methods for surveillance of antimalarial drug efficacy. 2009;

786 26. ZAMEP. Zanzibar guidelines for malaria diagnosis and treatment: Zanzibar 787 malaria elimination programme. Zanzibar: ZAMEP; 2014.

788 27. Ministry of Health. National Guidelines for Diagnosis and Treatment of Malaria. Dar es Salaam, Tanzania, Ministry of Health and Social Welfare, 789 790 United Republic of Tanzania; 2014.

- 791 28. WHo. Tackling emerging antimalarial drug resistance in Africa [Internet]. 792 Available from: https://www.who.int/news/item/18-11-2022-tackling-emerging-793 antimalarial-drug-resistance-in-africa
- 794 29. World Health Organization. Methods and Techniques for Clinical Trials on 795 Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations. 796 Genève, Switzerland: World Health Organization; 2007.

797 30. WHO. Informal consultation on methodology to distinguish reinfection from 798 recrudescence in high malaria transmission areas: report of a virtual meeting, 799 17–18 May 2021 [Internet]. World Health Organization; 2021. Available from: 800 https://play.google.com/store/books/details?id=t3VyEAAAQBAJ

31. Anderson TJ, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, 801 802 Mollinedo R, et al. Microsatellite markers reveal a spectrum of population 803 structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol 804 [Internet]. 2000;17:1467-82. Available from: 805 http://dx.doi.org/10.1093/oxfordjournals.molbev.a026247

medRxiv preprint doi: https://doi.org/10.1101/2023.12.02.23299314; this version posted December 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 806 32. Tanzania ZA, Others. Tanzania: HIV/AIDS and malaria indicator survey 807 2007-08. Tanzania: HIV/AIDS and malaria indicator survey 2007-08 [Internet].
- 2008: 808

Available

from:

https://www.cabdirect.org/cabdirect/abstract/20093087732 809

33. Tanzania HIV/AIDS and Malaria Indicator Survey, 2011-12 [Internet]. 810 Commission for AIDS 811 Tanzania (TACAIDS): 2014. Available from: 812 https://play.google.com/store/books/details?id=-KnsnQEACAAJ

- 813 34. Demographic T. health survey and malaria indicator survey (TDHS-MIS) 2015--16. Dar es Salaam/Tanzania. 2016; 814
- 815 35. Ellman R, Maxwell C, Finch R, Shayo D. Malaria and anaemia at different 816 altitudes in the Muheza district of Tanzania: childhood morbidity in relation to level of exposure to infection. Ann Trop Med Parasitol [Internet]. 1998;92:741-817 818 53. Available from: http://dx.doi.org/10.1080/00034989858989
- 819 36. Ishengoma DS, Mmbando BP, Mandara CI, Chiduo MG, Francis F, Timiza 820 W, et al. Trends of Plasmodium falciparum prevalence in two communities of 821 Muheza district North-eastern Tanzania: correlation between parasite 822 prevalence, malaria interventions and rainfall in the context of re-emergence of 823 malaria after two decades of progressively declining transmission. Malar J 824 [Internet]. 2018 [cited 2023 Nov 29];17:1–10. Available from: 825 https://malariajournal.biomedcentral.com/articles/10.1186/s12936-018-2395-1
- 826 37. Smith T, Charlwood JD, Kihonda J, Mwankusye S, Billingsley P, Meuwissen 827 J, et al. Absence of seasonal variation in malaria parasitaemia in an area of 828 intense seasonal transmission. Acta Trop [Internet]. 1993;54:55-72. Available from: http://dx.doi.org/10.1016/0001-706x(93)90068-m 829
- 830 38. Mandara CI. Francis F. Chiduo MG. Ngasala B. Mandike R. Mkude S. et al. 831 rates tolerability of artesunate-amodiaguine Hiah cure and and 832 dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum 833 malaria in Kibaha and Kigoma, Tanzania. Malar J [Internet]. 2019;18:99. 834 Available from: http://dx.doi.org/10.1186/s12936-019-2740-z
- 835 39. Chacky F, Runge M, Rumisha SF, MacHafuko P, Chaki P, Massaga JJ, et 836 al. Nationwide school malaria parasitaemia survey in public primary schools, 837 the United Republic of Tanzania. Malar J [Internet]. 2018;17:1–16. Available https://malariajournal.biomedcentral.com/articles/10.1186/s12936-018-838 from: 839 2601-1
- 840 40. Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, Félix J, et 841 al. Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, 842 and dihydroartemisinin-piperaguine for the treatment of uncomplicated 843 Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar J 844 [Internet]. 2018;17:144. Available from: http://dx.doi.org/10.1186/s12936-018-845 2290-9
- 846 41. Chenet SM, Okoth SA, Kelley J, Lucchi N, Huber CS, Vreden S, et al. 847 Molecular Profile of Malaria Drug Resistance Markers of Plasmodium falciparum in Suriname. Antimicrob Agents Chemother [Internet]. 2017;61. 848

- 849 Available from: http://dx.doi.org/10.1128/AAC.02655-16
- 850 42. Fstat JG. a computer program to calculate F-statistics. J Hered.

851 43. Haubold B, Hudson RR. LIAN 3.0: detecting linkage disequilibrium in 852 multilocus data. Bioinformatics [Internet]. 2000 [cited 2023 Nov 26];16:847-9. 853 Available https://academic.oup.com/bioinformatics/articlefrom: abstract/16/9/847/307695 854

855 44. Evanno G, Regnaut S, Goudet J. Detecting the number of clusters of individuals using the software STRUCTURE: a simulation study. Mol Ecol 856 [Internet]. 2005;14:2611-20. Available from: http://dx.doi.org/10.1111/j.1365-857 858 294X.2005.02553.x

45. Earl DA, vonHoldt BM. STRUCTURE HARVESTER: a website and program 859 for visualizing STRUCTURE output and implementing the Evanno method. 860 861 Conserv Genet Resour [Internet]. 2012;4:359-61. Available from: https://doi.org/10.1007/s12686-011-9548-7 862

46. Jakobsson M, Rosenberg NA. CLUMPP: a cluster matching and 863 864 permutation program for dealing with label switching and multimodality in analysis of population structure. Bioinformatics [Internet]. 2007;23:1801-6. 865 866 Available from: http://dx.doi.org/10.1093/bioinformatics/btm233

867 47. Nei M. Molecular Evolutionary Genetics [Internet]. Columbia University Available 868 Press; 1987. from: 869 https://play.google.com/store/books/details?id=UhRSsLkixDgC

48. Goudet J. hierfstat, a package for r to compute and test hierarchical F-870 871 Mol Ecol Notes [Internet]. 2005;5:184–6. statistics. Available from: 872 https://onlinelibrary.wiley.com/doi/10.1111/j.1471-8286.2004.00828.x

873 49. Jombart T. adegenet: a R package for the multivariate analysis of genetic 874 markers. Bioinformatics [Internet]. 2008;24:1403-5. Available from: 875 http://dx.doi.org/10.1093/bioinformatics/btn129

876 50. Paradis E, Claude J, Strimmer K. APE: Analyses of Phylogenetics and 877 Evolution in R language. Bioinformatics [Internet]. 2004;20:289-90. Available from: http://dx.doi.org/10.1093/bioinformatics/btg412 878

- 879 51. Nkhoma SC, Nair S, Cheeseman IH, Rohr-Allegrini C, Singlam S, Nosten F, et al. Close kinship within multiple-genotype malaria parasite infections. Proc 880 881 Biol Sci [Internet]. 2012;279:2589-98. Available from: 882 http://dx.doi.org/10.1098/rspb.2012.0113
- 52. Jost L. GST and its relatives do not measure differentiation. Mol Ecol 883 884 [Internet]. 2008;17:4015-26. Available from: https://doi.org/10.1111/j.1365-885 294X.2008.03887.x

53. WHO. Informal consultation on methodology to distinguish reinfection from 886 887 recrudescence in high malaria transmission areas: report of a virtual meeting, 888 17–18 May 2021 [Internet]. World Health Organization; 2021. Available from:

889 https://play.google.com/store/books/details?id=t3VyEAAAQBAJ

890 54. Jones S, Plucinski M, Kay K, Hodel EM, Hastings IM. A Computer Modelling Approach To Evaluate the Accuracy of Microsatellite Markers for Classification 891 892 of Recurrent Infections during Routine Monitoring of Antimalarial Drug Efficacy. 893 2020;64. Antimicrob Agents Chemother [Internet]. Available from: 894 http://dx.doi.org/10.1128/AAC.01517-19

895 55. Plucinski MM, Barratt JLN. Nonparametric Binary Classification to 896 Distinguish Closely Related versus Unrelated Plasmodium falciparum Parasites. Am J Trop Med Hyg [Internet]. 2021;104:1830-5. Available from: 897 898 http://dx.doi.org/10.4269/ajtmh.21-0117

56. Hastings IM, Felger I. WHO antimalarial trial guidelines: good science, bad 899 Trends Parasitol [Internet]. 900 news? 2022;38:933-41. Available from: 901 http://dx.doi.org/10.1016/j.pt.2022.08.005

902 57. Nkhoma SC, Trevino SG, Gorena KM, Nair S, Khoswe S, Jett C, et al. Co-903 transmission of Related Malaria Parasite Lineages Shapes Within-Host 904 Parasite Diversity. Cell Host Microbe [Internet]. 2020;27:93-103.e4. Available 905 from: http://dx.doi.org/10.1016/j.chom.2019.12.001

906 58. Bérubé S, Freedman B, Menya D, Kipkoech J, Abel L, Lapp Z, et al. 907 Superinfection plays an important role in the acquisition of complex 908 Plasmodium falciparum infections among female Anopheles mosquitoes 909 [Internet]. bioRxiv. 2022 [cited 2023 Nov 30]. p. 2022.12.23.521802. Available 910 from: https://www.biorxiv.org/content/10.1101/2022.12.23.521802v1

911 59. Fola AA, Harrison GLA, Hazairin MH, Barnadas C, Hetzel MW, Iga J, et al. 912 Higher Complexity of Infection and Genetic Diversity of Plasmodium vivax Than Plasmodium falciparum Across All Malaria Transmission Zones of Papua New 913 914 Guinea. Am J Trop Med Hyg [Internet]. 2017;96:630-41. Available from: 915 http://dx.doi.org/10.4269/ajtmh.16-0716

916 60. Schultz L, Wapling J, Mueller I, Ntsuke PO, Senn N, Nale J, et al. Multilocus 917 haplotypes reveal variable levels of diversity and population structure of 918 Plasmodium falciparum in Papua New Guinea, a region of intense perennial 919 transmission. Malar J [Internet]. 2010;9:336. Available from: 920 http://dx.doi.org/10.1186/1475-2875-9-336

921 61. Barry AE, Schultz L, Senn N, Nale J, Kiniboro B, Siba PM, et al. High levels 922 of genetic diversity of Plasmodium falciparum populations in Papua New Guinea despite variable infection prevalence. Am J Trop Med Hyg [Internet]. 923 924 2013;88:718–25. Available from: http://dx.doi.org/10.4269/ajtmh.12-0056

925 62. Noviyanti R, Coutrier F, Utami RAS, Trimarsanto H, Tirta YK, Trianty L, et 926 al. Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and 927 P. falciparum: Implications for Malaria Control and Elimination. PLoS Negl Trop 928 Dis [Internet]. 2015;9:e0003739. Available from: 929 http://dx.doi.org/10.1371/journal.pntd.0003739

63. Kattenberg JH, Razook Z, Keo R, Koepfli C, Jennison C, Lautu-Gumal D, 930

medRxiv preprint doi: https://doi.org/10.1101/2023.12.02.23299314; this version posted December 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

931 et al. Monitoring Plasmodium falciparum and Plasmodium vivax using 932 microsatellite markers indicates limited changes in population structure after 933 substantial transmission decline in Papua New Guinea. Mol Ecol [Internet]. 2020;29:4525-41. Available from: http://dx.doi.org/10.1111/mec.15654 934

935 64. Sáenz FE, Morton LC, Okoth SA, Valenzuela G, Vera-Arias CA, Vélez-936 Álvarez E. et al. Clonal population expansion in an outbreak of Plasmodium 937 falciparum on the northwest coast of Ecuador. Malar J [Internet]. 2015;13 Suppl 938 1:497. Available from: http://dx.doi.org/10.1186/s12936-015-1019-2

939 65. Griffing SM, Mixson-Hayden T, Sridaran S, Alam MT, McCollum AM, 940 Cabezas C, et al. South American Plasmodium falciparum after the malaria 941 eradication era: clonal population expansion and survival of the fittest hybrids. 942 PLoS One [Internet]. 2011;6:e23486. Available from: 943 http://dx.doi.org/10.1371/journal.pone.0023486

944 66. Volkman SK, Ndiave D, Diakite M, Koita OA, Nwakanma D, Daniels RF, et 945 al. Application of genomics to field investigations of malaria by the international 946 centers of excellence for malaria research. Acta Trop [Internet]. 2012;121:324-947 32. Available from: http://dx.doi.org/10.1016/j.actatropica.2011.12.002

948 67. WHO. Informal consultation on methodology to distinguish reinfection from 949 recrudescence in high malaria transmission areas. 2021;

950 68. Moser KA, Madebe RA, Aydemir O, Chiduo MG, Mandara CI, Rumisha SF, 951 et al. Describing the current status of Plasmodium falciparum population 952 structure and drug resistance within mainland Tanzania using molecular 953 inversion probes. Mol Ecol [Internet]. 2021;30:100-13. Available from: 954 http://dx.doi.org/10.1111/mec.15706

955 69. Morgan AP. Brazeau NF. Ngasala B. Mhamilawa LE. Denton M. Msellem M, et al. Falciparum malaria from coastal Tanzania and Zanzibar remains highly 956 957 connected despite effective control efforts on the archipelago. Malar J [Internet]. 958 2020;19:47. Available from: http://dx.doi.org/10.1186/s12936-020-3137-8

959 70. Wahlund S. ZUSAMMENSETZUNG VON POPULATIONEN UND 960 KORRELATIONSERSCHEINUNGEN VOM **STANDPUNKT** DER 961 VERERBUNGSLEHRE AUS BETRACHTET. Hereditas [Internet]. 2010;11:65-962 106. Available from: http://doi.wiley.com/10.1111/j.1601-5223.1928.tb02483.x

71. Ruybal-Pesántez S, Tiedje KE, Rorick MM, Amenga-Etego L, Ghansah A, 963 R Oduro A, et al. Lack of Geospatial Population Structure Yet Significant 964 Linkage Disequilibrium in the Reservoir of Plasmodium falciparum in Bongo 965 966 District, Ghana. Am J Trop Med Hyg [Internet]. 2017;97:1180–9. Available from: 967 http://dx.doi.org/10.4269/ajtmh.17-0119

72. Durand P, Michalakis Y, Cestier S, Oury B, Leclerc MC, Tibayrenc M, et al. 968 Significant linkage disequilibrium and high genetic diversity in a population of 969 970 Plasmodium falciparum from an area (Republic of the Congo) highly endemic 971 for malaria. Am J Trop Med Hyg [Internet]. 2003 [cited 2023 Nov 26];68:345-9. 972 Available from: https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=d87c03de1 973

974 746b4fdd6e8cfb4f59c316e0cfe1651

975 73. Fola AA, Nate E, Abby Harrison GL, Barnadas C, Hetzel MW, Iga J, et al. 976 Nationwide genetic surveillance of Plasmodium vivax in Papua New Guinea 977 reveals heterogeneous transmission dynamics and routes of migration 978 amongst subdivided populations. Infect Genet Evol [Internet]. 2018;58:83-95. 979 Available from: http://dx.doi.org/10.1016/j.meegid.2017.11.028

74. Waltmann A, Koepfli C, Tessier N, Karl S, Fola A, Darcy AW, et al. 980 981 Increasingly inbred and fragmented populations of Plasmodium vivax 982 associated with the eastward decline in malaria transmission across the 983 Southwest Pacific. PLoS Negl Trop Dis [Internet]. 2018;12:e0006146. Available 984 from: http://dx.doi.org/10.1371/journal.pntd.0006146

75. Madesis P, Ganopoulos I, Tsaftaris A. Microsatellites: evolution and 985 986 contribution. Methods Mol Biol [Internet]. 2013;1006:1-13. Available from: 987 http://dx.doi.org/10.1007/978-1-62703-389-3_1

988 76. Avdemir O, Janko M, Hathaway NJ, Verity R, Mwandagalirwa MK, Tshefu 989 AK, et al. Drug-Resistance and Population Structure of Plasmodium falciparum 990 Across the Democratic Republic of Congo Using High-Throughput Molecular 991 Inversion Probes. J Infect Dis [Internet]. 2018;218:946-55. Available from: 992 http://dx.doi.org/10.1093/infdis/jiy223

993 77. Tessema SK, Raman J, Duffy CW, Ishengoma DS, Amambua-Ngwa A, 994 Greenhouse B. Applying next-generation sequencing to track falciparum 995 malaria in sub-Saharan Africa. Malar J [Internet]. 2019;18:268. Available from: 996 http://dx.doi.org/10.1186/s12936-019-2880-1

997 78. Daniels R, Volkman SK, Milner DA, Mahesh N, Neafsey DE, Park DJ, et al. A general SNP-based molecular barcode for Plasmodium falciparum 998 999 identification and tracking. Malar J [Internet]. 2008;7:223. Available from: 1000 http://dx.doi.org/10.1186/1475-2875-7-223

1001 79. Miller RH, Hathaway NJ, Kharabora O, Mwandagalirwa K, Tshefu A, 1002 Meshnick SR, et al. A deep sequencing approach to estimate Plasmodium 1003 falciparum complexity of infection (COI) and explore apical membrane antigen 1004 diversity. Malar J [Internet]. 2017;16:490. Available 1 from: 1005 http://dx.doi.org/10.1186/s12936-017-2137-9

1006 80. Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, et 1007 al. Development of amplicon deep sequencing markers and data analysis pipeline for genotyping multi-clonal malaria infections. BMC Genomics 1008 1009 [Internet]. 2017;18:864. Available from: http://dx.doi.org/10.1186/s12864-017-1010 4260-y

81. Lerch A, Koepfli C, Hofmann NE, Kattenberg JH, Rosanas-Urgell A, Betuela 1011 I, et al. Longitudinal tracking and quantification of individual Plasmodium 1012 1013 falciparum clones in complex infections. Sci Rep [Internet]. 2019;9:3333. 1014 Available from: http://dx.doi.org/10.1038/s41598-019-39656-7

1015 82. Juliano JJ, Porter K, Mwapasa V, Sem R, Rogers WO, Ariey F, et al.

1016 Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing. Proc Natl Acad Sci 1017 2010;107:20138-43. 1018 [Internet]. Available from: U S А http://dx.doi.org/10.1073/pnas.1007068107 1019

1020 83. Auburn S, Benavente ED, Miotto O, Pearson RD, Amato R, Grigg MJ, et al. Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population 1021 1022 reveals selective pressures and changing transmission dynamics. Nat 1023 Commun [Internet]. 2018;9:2585. Available from: 1024 http://dx.doi.org/10.1038/s41467-018-04965-4.